deltatrials
Completed PHASE1 NCT00000649

An Open-Label, Staggered Rising Dose Cohort Study Assessing the Pharmacokinetics, Safety, and Tolerance of BI-RG-587 in Combination With Zidovudine in Patients With HIV Infection (CD4+ Cell Count < 400/mm3)

Sponsor: Boehringer Ingelheim

Conditions HIV Infections
Interventions Nevirapine Zidovudine
Updated 5 times since 2017 Last updated: Jul 29, 2008

A PHASE1 clinical study on HIV Infections, this trial is completed. The trial is conducted by Boehringer Ingelheim and has accumulated 5 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

5 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE1

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  3. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  4. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

  5. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE1

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Boehringer Ingelheim
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Birmingham, United States
  • • San Diego, United States
  • • Worcester, United States